Zusammenfassung
Der Rhapontikrhabarberwurzel-Extrakt ERr 731® hat in bis zu 2-jährigen Studien seine
Wirksamkeit und Sicherheit in der Behandlung von Wechseljahresbeschwerden belegt.
Hitzewallungen wurden nach 8 und 12 Wochen, gemessen mit dem HFWWS, stärker reduziert,
als in niedrig dosierten Hormontherapien.
Summary
Special extract ERr 731® from the roots of Rheum rhaponticum for the treatment of menopausal symptoms Clinical studies entailing two-year application
of ERr 731® have proved its efficacy and safety in the treatment of menopausal symptoms.
For example, after 8 and 12 weeks ERr 731® has been shown to severely reduce menopausal
hot flushes measured by Hot Flush Weekly Weighted Score (HFWWS) compared to low-dose
hormone therapy.
Schlüsselwörter
Rheum rhaponticum
- Perimenopause - Hot Flush Weekly Weighted Score (HFWWS) - Menopause Rating Scale
- Anxiety Inventory Scale - Depression Inventory Scale
Key words
Rheum rhaponticum
- Perimenopause - Hot Flush Weekly Weighted Score (HFWWS) - Menopause Rating Scale
- Anxiety Inventory Scale - Depression Inventory Scale
Literatur
- 1 European Medicines Agency .Community herbal monograph on Rheum palmatum L. and Rheum
officinale Baillon, radix. EMEA/HMPC 2007: 189624
- 2
Kaszkin-Bettag M.
Vollmer G.
Rettenberger R.
Heger P W.
Rhapontikrhabarberwurzel zur Behandlung von menopausalen Beschwerden.
Erfahrungsheilk.
2009;
58
70-77
- 3
Heger M.
Ventskovskiy B M.
Borzenko I et al..
Efficacy and safety of a special extract of Rheum rhaponticum (ERr 731) in perimenopausal
women with climacteric complaints: A 12-week randomized, double-blind, placebo-controlled
trial.
Menopause.
2006;
13
744-759
- 4
Schulz V.
Sibirischer Rhabarber bei klimakterischen Beschwerden.
Z Phytother.
2007;
28
24-25
- 5
Hauser G A.
Potthoff P.
Rosemeier P J.
Schneider H PG.
Die Selbstbeurteilungs-Skala für klimakterische Beschwerden (Menopause Rating Scale
II).
J Menopause.
1999;
6
12-15
- 6
Potthoff P.
Heinemann L A.
Schneider H P et al..
Menopause-Rating-Skala (MRS II): Methodische Standardisierung in der deutschen Bevölkerung.
Zentralbl Gynakol.
2000;
122
280-286
http://www.menopause-rating-scale.info
- 7 Kraft K. Stange R. Lehrbuch Naturheilverfahren. Stuttgart: Hippokrates; 2010: 609
- 8
Panay N.
Ylikorkala O.
Archer D F et al..
Ultra-low-dose estradiol and norethisterone acetate: effective menopausal symptom
relief.
Climacteric.
2007;
10
120-131
- 9
Kaszkin-Bettag M.
Ventskovskiy B M.
Kravchenko A et al..
The special extract ERr 731 of the roots of Rheum rhaponticum decreases anxiety and
improves health state and general well-being in perimenopausal women.
Menopause.
2007;
14
270-283
- 10
Kaszkin-Bettag M.
Rettenberger R.
Heger P W.
Der Spezialextrakt ERr 731 aus der Wurzel des Rhapontikrhabarbers (Rheum rhaponticum):
Wirksamkeit bei Kopfschmerz/ Migräne und weiteren klimakterischen Beschwerden bei
Frauen in der Perimenopause.
Schweizer Zeitschr Phytother.
2007;
2
24-30
- 11
Hasper I.
Ventskovskiy B M.
Rettenberger R et al..
Long-term efficacy and safety of the special extract ERr 731 of Rheum rhaponticum
in perimenopausal women with climacteric complaints.
Menopause.
2009;
16
117-131
- 12
Kaszkin-Bettag M.
Hasper I.
Heger P W.
Spezialextrakt ERr 731® aus der Rhapontikrhabarberwurzel bei menopausalen Beschwerden,
Langzeitstudie bestätigt Wirksamkeit.
Schweizer Zeitschr Phytother.
2008;
8
9-12
- 13
Notelovitz M.
Lenihan J P.
McDermott M et al..
Initial 17ß-Estradiol dose for treating vasomotor symptoms.
Obstet Gynecol.
2000;
95
726-731
- 14
Kaszkin-Bettag M.
Ventskovskiy B.
Solskyy S et al..
Confirmation of the efficacy of ERr 731® in perimenopausal women with menopausal symptoms.
Altern Ther Health Med.
2009;
15
24-34
- 15
Bachmann C.
Bestätigung der Wirksamkeit von ERr 731 bei perimenopausalen Frauen mit menopausalen
Beschwerden.
Schweizer Zeitschr Phytother.
2009;
6
18-20
- 16
Heinemann L A.
Potthoff P.
Schneider H P.
International versions of the Menopause Rating Scale.
Health Qual Life Outcomes.
2003;
1
28
- 17
Heinemann K.
Ruebig A.
Potthoff P et al..
The Menopause Rating Scale (MRS) scale: a methodological review.
Health Qual Life Outcomes.
2004;
2
45
- 18
Dinger J.
Zimmermann T.
Heinemann L A.
Stoehr D.
Quality of life and hormone use: new validation results of MRS scale.
Health Qual Life Outcomes.
2006;
4
32
- 19 Medical Products Agency (Lakemedelsverket) Sweden .Public assessment report, scientific
discussion, Eviana/Activelle. SE/H/150/02/MR; 2008
- 20 European Medicines Agency (EMA) .Activelle, article 29 referral, annex I (Liste
der Arzneimittelnamen), Annex II (Wissenschaftliche Schlussfolgerungen), Annex III
(Zusammenfassung der Merkmale des Arzneimittels). 25.09.2009
- 21 Novo Nordisk Canada Inc .Activelle LD Product Monograph 0,5 mg Estradiol and 0,1
mg NETA. Date of Revision 17.04.2008: page 27 of 38
- 22 ERr 004-DB Clinical Trial Report
- 23
Beck A T.
Epstein N.
Brown G.
Steer R A.
An inventory for measuring clinical anxiety: Psychometric properties.
J Consult Clin Psychol.
1988;
56
893-897
- 24 Beck A T. Steer R A. Brown G K. BDI-II Manual. San Antonio, TX: The Psychological
Corporation; 1996
- 25
Beer A M.
Kneis K C.
Rettenberger R et al..
Wirksamkeit von Phytoestrol® N (Extrakt Rheum rhaponticum ERr 731) bei klimakterischen
Beschwerden: Ergebnisse einer sechsmonatigen, prospektiven Anwendungsbeobachtung mit
Phytoestrol® N.
J Menopause.
2007;
3
8-15
- 26
Kaszkin-Bettag M.
Beck S.
Richardson A et al..
Efficacy of the special extract ERr 731 from rhapontic rhubarb for menopausal complaints:
A 6-month open observational study.
Altern Ther Health Med.
2008;
14
32-38
- 27
Schulz V.
AWB mit 363 peri- und postmenopausalen Frauen belegt Verträglichkeit und Wirksamkeit.
Z Phytother.
2009;
30
178-179
- 28 European Medicines Agency .Guideline on clinical investigation of medicinal products
for hormone replacement therapy of oestrogen deficiency symptoms in postmenopausal
women. EMEA/CHMP/021/097, Rev. 1; 2005, http://www.emea.europa.eu/pdfs/human/ewp/002197en.pdf
- 29
Chlebowski R T.
Anderson G L.
Gass M et al..
Estrogen plus progestin and breast cancer incidence and mortality in postmenopausal
women.
J Am Med Assoc.
2010;
304
1684-1692
- 30
Grady D.
Breast cancer seen as riskier with hormone. Interview mit Rowan Chlebowski.
New York Times.
2010;
http://www.nytimes.com/2010/10/20/health/20hormone.html?_r=1&scp=1&sq=chlebowski&st=cse
- 31 Obi N. Pflanzenpräparate bei Wechseljahresbeschwerden und Brustkrebsrisiko – Datenanalyse
einer populationsbezogenen Fall-Kontroll-Studie. Saarbrücken: Südwestdt Verlag für
Hochschulschriften; 2009: 1-64
- 32
Obi N.
Chang-Claude J.
Berger J et al..
The use of herbal preparations to alleviate climacteric disorders and risk of postmenopausal
breast cancer in a German case-control study.
Cancer Epidemiol Biomarkers Prev.
2009;
18
2207-2213
- 33
Becher H.
Kostev K.
Schröder-Bernhardi D.
Validity and representativeness of the »Disease Analyzer« patient database for use
in pharmacoepidemiological and pharmacoeconomic studies.
Int J Clin Pharmacol Ther.
2009;
47
617-626
- 34
Zepelin H H.
Meden H.
Kostev K et al..
Isopropanolic black cohosh extract and recurrence-free survival after breast cancer.
Int J Clin Pharmacol Ther.
2007;
45
143-154
- 35
Yue W.
Wang J P.
Li Y et al..
Effects of estrogen on breast cancer development: Role of estrogen receptor independent
mechanisms.
Int J Cancer.
2010;
127
1748-1757
- 36
Möller F.
Zierau O.
Jandausch A et al..
Subtype-specific activation of estrogen receptors by a special extract of Rheum rhaponticum
(ERr 731), its aglycones and structurally related compounds in U2OS human osteosarcoma
cells.
Phytomedicine.
2007;
14
716-726
- 37
Wober J.
Möller F.
Richter T et al..
Activation of estrogen receptor-beta by a special extract of Rheum rhaponticum (ERr
731), its aglycones and structurally related compounds.
J Steroid Biochem Mol Biol.
2007;
107
191-201
- 38
Zhao C.
Matthews J.
Tujague M et al..
Estrogen receptor beta2 negatively regulates the transactivation of estrogen receptor
alpha in human breast cancer cells.
Cancer Res.
2007;
67
3955-3962
- 39
McDonnel D P.
Wardell S E.
The molecular mechanisms underlying the pharmacological actions of ER modulators:
implications for new drug discovery in breast cancer.
Curr Opin Pharmacol.
2010;
10
1-9
- 40
Lindberg K.
Ström A.
Lock J G et al..
Expression of estrogen receptor beta increases integrin alpha1 and integrin beta1
levels and enhances adhesion of breast cancer cells.
J Cell Physiol.
2010;
222
156-167
- 41
Hartman J.
Ström A.
Gustaffsson J A.
Estrogen receptor beta in breast cancer diagnostic and therapeutic implications.
Steroids.
2009;
74
635-641
- 42
Zilli M.
Grassadonia N.
Tinari N et al..
Molecular mechanisms of endocrine resistance and their implication in the therapy
of breast cancer.
Biochim Biophys Acta.
2009;
1795
62-81
- 43
Warner M.
Gustafsson J A.
The role of estrogen receptor ß (ERß) in malignant diseases a new potential target
for antiproliferative drugs in prevention and treatment of cancer.
Biochem Biophys Res Commun.
2010;
396
63-66
- 44
Shanle E K.
Xu W.
Selectively targeting estrogen receptors for cancer treatment.
Adv Drug Deliv Rev.
2010;
[in press]
- 45
Imwalle D B.
Gustafsson J A.
Rissman E F.
Lack of functional estrogen receptor beta influences anxiety behavior and serotonin
content in female mice.
Physiol Behav.
2005;
84
157-163
- 46
Vollmer G.
Papke A.
Zierau O.
Treatment of menopausal symptoms by an extract from the roots of rhapontic rhubarb:
the role of estrogen receptors.
Chin Med.
2010;
5
7
- 47
Papke A.
Kretzschmar G.
Zierau O et al..
Effects of the special extract ERr 731® from Rheum rhaponticum on estrogen-regulated
targets in the uterotrophy model of ovariectomized rats.
J Steroid Biochem Mol Biol.
2009;
117
176-184
- 48
Kaszkin-Bettag M.
Richardson A.
Rettenberger R.
Heger P W.
Long-term toxicity studies in dogs support the safety of the special extract ERr 731
from the roots of Rheum rhaponticum.
Food Chem Toxicol.
2008;
46
1608-1618
- 49 Chemisch-Pharmazeutische Fabrik Göppingen Carl Müller .Phyto-Strol Gebrauchinformation
und Fachinformation; 2009. http://www.mueller-goeppingen.de/media/files/BP-Arzneimittel/phyto-strol-2009.pdf
- 50 Huber R. Mind-Maps Phytotherapie. Stuttgart: Hippokrates; 2009: 101
Peter W Heger
Health Research Services GmbH
Zeutern
Hofäckerstr. 14
76698 Ubstadt-Weiher
eMail: peter.heger@h-r-s.biz
Online
http://dx.doi.org/10.1055/s-0030-1262407